evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,703 questions · 15,007 findings · 1,416 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Antidepressant plus antipsychotic vs placebo plus antidepressant

Change in depression severity from baseline · adults with psychotic depression

The review found no eligible studies for this question.

2 findings from 1 review

Antidepressant plus antipsychotic vs placebo plus antidepressant

Acceptability ‐ dropouts due to adverse effects · adults with psychotic depression

The review found no eligible studies for this question.

2 findings from 1 review

Antipsychotics vs placebo

Clinical response of depression · adults with psychotic depression

It is very uncertain whether antipsychotic changes clinical response of depression compared with placebo (very low certainty).

1 finding from 1 review

Immunosuppressive treatment vs placebo/no treatment/non‐immunosuppressive supportive treatment

Death at final · primary membranous nephropathy in adults with nephrotic syndrome

Immunosuppressive treatment showed no clear difference in death at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Death at final · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids showed no clear difference in death at final compared with placebo/no treatment/steroids (low certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids probably leads to lower end‐stage kidney disease at final compared with placebo/no treatment/steroids (moderate certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids probably leads to higher total remission (complete or partial) at final compared with placebo/no treatment/steroids (moderate certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Complete remission · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids probably leads to higher complete remission at final compared with placebo/no treatment/steroids (moderate certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Relapse · primary membranous nephropathy in adults with nephrotic syndrome

It is very uncertain whether oral alkylating agents ± steroids changes recurrence of disease (relapse) at final compared with placebo/no treatment/steroids (very low certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids showed no clear difference in 100% increase in serum creatinine at final compared with placebo/no treatment/steroids (moderate certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids may leads to higher adverse events ‐ temporary/permanent discontinuation or… compared with placebo/no treatment/steroids (low certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Adverse events ‐ infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome

It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ infection at 3 years compared with placebo/no treatment/steroids (very low certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome

It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ malignancy at final compared with placebo/no treatment/steroids (very low certainty).

1 finding from 1 review

Calcineurin inhibitors ± steroids vs placebo/no treatment/supportive treatment/steroids

Death at final · primary membranous nephropathy in adults with nephrotic syndrome

It is very uncertain whether calcineurin inhibitors ± steroids changes death at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).

1 finding from 1 review

Immunosuppressive treatment vs placebo/no treatment/non‐immunosuppressive supportive treatment

End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome

Immunosuppressive treatment probably leads to lower end‐stage kidney disease at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).

1 finding from 1 review